Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 12, 2002 - Issue 9
Submit an article Journal homepage
30
Views
1
CrossRef citations to date
0
Altmetric
Miscellaneous

BAFF et al.: novel members of the TNF ligand and receptor families as therapeutic targets

Francis J Dumont Merck Research Laboratories, RY80W107, 126 Lincoln Avenue, Rahway 07065 NJ, USA
Pages 1351-1365 | Published online: 25 Feb 2005

Bibliography

  • LOCKSLEY RM, KILLEEN N, LENARDO MJ: The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell(2001) 104:487–501.
  • •Comprehensive review of the molecular biology of TNF ligand/receptor superfarnilies.
  • BODMER JL, SCHNEIDER P, TSCHOPP J: The molecular architecture of the TNF superfamily. Trends Biochem. Sci. (2002) 27:19–26.
  • MAK TW, YEH WC: Signalling for survival and apoptosis in the immune system. Arthritis Res. (2002) 4(Suppl.):243–252.
  • CHEN G, GOEDDEL DV: TNF-R1 signalling: a beautiful pathway. Science (2002) 296: 1634-1635.
  • ADAMS AB, LARSEN CP, PEARSON TC, NEWELL KA: The role of TNF receptor and TNF superfamily molecules in organ transplantation. Am. j Transplant. (2002) 2:12–18.
  • O'SHEA JJ, MA A, LIPSKY P: Cytokines and autoimmunity. Nat. Rev Immunol (2002) 2:37–45.
  • VAN ASSCHE G, RUTGEERTS P: AntiTNF agents in Crohn's disease. Expert Opin. Investig. Drugs. (2000) 9:103–111.
  • HAMILTON K, CLAIR EW: Tumour necrosis factor-a blockade: a new era for effective management of rheumatoid arthritis. Expert. Opin. Pharmacother. (2000) 1:1041–1052.
  • BURKLY LC: CD40 pathway blockade as an approach to immunotherapy. Adv. Exp. Med. Biol. (2001) 489:135–152.
  • BRAMS P, BLACK A, PADLAN EA et al: A humanized antihuman CD154 monoclonal antibody blocks CD154-CD40 mediated human B cell activation. mt. Immunopharmacol (2001) 1:277–294.
  • BOON L, BROK HP, BAUER J et al: Prevention of experimental autoimmune encephalomyelitis in the common marmoset (Callithrixjacchus) using a chimeric antagonist monoclonal antibody against human CD40 is associated with altered B cell responses. Immunol (2001) 167:2942–2949.
  • KHARE SD, HSU H: The role of TALL-1 and APRIL in immune regulation. Trends Immunol (2001) 22:61–63.
  • LIPSKY PE: Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat. Immunot (2001) 2:764–766.
  • MACKAY F, BROWNING JL: BAFF: a fundamental survival factor for B cells. Nat. Rev Immunol (2002) 2:465–475.
  • ••Excellent review of the current knowledgeon BAFF and its role in B cell immunity.
  • DO RK, CHEN-KIANG S: Mechanism of BLyS action in B cell immunity. Cytokine Growth Factor Rev (2002) 13:19–25.
  • MACKAY F, MACKAY CR: The role of BAFF in B cell maturation, T cell activation and autoimmunity. Trends Immunol (2002) 23:113–115.
  • ROLINK AG, MELCHERS F: BAFFled B cells survive and thrive: roles of BAFF in B cell development. Curt: Opin. Immunol (2002) 14:266–275.
  • SCHNEIDER P, MACKAY F, STEINER V et al: BAFF, a novel ligand of the tumour necrosis factor family, stimulates B cell growth. I Exp. Med. (1999) 189:1747–1756.
  • ••Initial description of BAFF as a member ofTNF ligand family that stimulates B cell growth.
  • MOORE PA, BELVEDERE O, ORR A et al: BLyS: member of the tumour necrosis factor family and B lymphocyte stimulator. Science (1999) 285:260–263.
  • ••Description of BAFF, under the nameBLyS, published shortly after reference 18.
  • TRIBOULEY C, WALLROTH M, CHAN V et al: characterisation of a new member of the TNF family expressed on antigen-presenting cells. Biol. Chem. (1999) 380:1443–1447.
  • SHU HB, HU WH, JOHNSON H: TALL-1 is a novel member of the TNF family that is downregulated by mitogens. Leukoc. Biol. (1999) 65:680–683.
  • NARDELLI B, BELVEDERE O, ROSCHKE V et al.: Synthesis and release of B lymphocyte stimulator from myeloid cells. Blood. (2001) 97:198–204.
  • MUKHOPADHYAY A, NI J, ZHAI Y, YU GL, AGGARWAL BB: Identification and characterisation of a novel cytokine, THANK, a TNF homologue that activates apoptosis, nuclear factor-kappaB and c-Jun NH2-terminal kinase. Biol. Chem. (1999) 274:15978–15981.
  • KARPUSAS M, CACHERO TG, QIAN F et al.: Crystal structure of extracellular human BAFF, a TNF family member that stimulates B lymphocytes.Biol. (2002) 315:1145–1154.
  • ••Structural characterisation of the extracellular region of BAFF and homology-based comparison with APRIL.
  • OREN DA, LI Y, VOLOVIK Y et al.: Structural basis of BLyS receptor recognition. Nat. Struct. Biol (2002) 9:288–292.
  • LIU Y, XU L, OPALKA N et al: Crystal structure of sTALL-1 reveals a virus-like assembly of TNF family ligands. Cell (2002) 108:383–394.
  • •Reports that BAFF forms virus-like assembly in crystals.
  • HAHNE M, KATAOKA T, SCHROTER M et al.: APRIL, a new ligand of the tumour necrosis factor family, stimulates tumour cell growth. I Exp. Med. (1998) 188:1185–1190.
  • ••Initial description of APRIL as a memberof the TNF ligand family that stimulates tumour cell growth.
  • KELLY K, MANOS E, JENSEN G, NADAULD L, JONES DA: APRIL/TRDL- 1, a tumour necrosis factor-like ligand, stimulates cell death. Cancer Res. (2000) 60:1021–1027.
  • LOPEZ-FRAGA M, FERNANDEZ R, ALBAR JP, HAHNE M: Biologically active APRIL is secreted following intracellular processing in the Golgi apparatus by furin convertase. EMBO Rep. (2001) 2:945–951.
  • GRAS MP, LAABI Y, LINARES-CRUZ G et al.: BCMAp: an integral membrane protein in the Golgi apparatus of human mature B lymphocytes. hat. Inanunol. (1995) 7:1093–1106.
  • MADRY C, LAABI Y, CALLEBAUT I et al.: The characterisation of murine BCMA gene defines it as a new member of the tumour necrosis factor receptor superfamily. hat Immunol (1998) 10:1693–1702.
  • HATZOGLOU A, ROUSSEL J, BOURGEADE MF et al: TNF receptor family member BCMA (B cell maturation) associates with TNF receptor-associated factor (TRAF) 1, TRAF2 and TRAF3 and activates NF-kappa B, elk-1, c-Jun N-terminal kinase and p38 mitogen-activated protein kinase. hannunol. (2000) 165:1322–1330.
  • THOMPSON JS, SCHNEIDER P, KALLED SL et al.: BAFF binds to the tumour necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population. J. Exp. Med. (2000) 192:129–135.
  • •Demonstrates that BAFF is a ligand for BCMA.
  • SHU HB, JOHNSON H: B cell maturation protein is a receptor for the tumour necrosis factor family member TALL-1. Proc. Natl. Acad. Sci. USA (2000) 97:9156–9161.
  • GROSS JA, JOHNSTON J, MUDRI S et al: TACT and BCMA are receptors for a TNF homologue implicated in B cell autoimmune disease. Nature (2000) 404:995–999.
  • ••Demonstrates that BAFF binds to TACTand BCMA and plays a role in favouring the development of SLE-like autoimmunity in mice.
  • MARSTERS SA, YAN M, PITTI P.M et al: Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACT. Carr. Biol. (2000) 10:785–788.
  • YU G, BOONE T, DELANEY J et al.: APRIL and TALL-I and receptors BCMA and TACT: system for regulating humoral immunity. Nat. Inmunol. (2000) 1:252–256.
  • RENNERT P, SCHNEIDER P, CACHERO TG et al.: A soluble form of B cell maturation antigen, a receptor for the tumour necrosis factor family member APRIL, inhibits tumour cell growth. I Exp. Med. (2000) 192:35–38.
  • XU S, LAM KP: B cell maturation protein, which binds the tumour necrosis factor family members BAFF and APRIL, is dispensable for humoral immune responses. Mol. Cell. Biol. (2001) 21:4067–4074.
  • •Deletion of BCMA does not affect B cell immunity.
  • SCHIEMANN B, GOMMERMAN JL, VORA K et al.: An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science (2001) 293:2111–2114.
  • ••Demonstrates that deletion of BAFF in mice blocks B cell development at the transitional Ti stage.
  • VON BULOW GU, BRAM RJ: NF-AT activation induced by a CAML-interacting member of the tumour necrosis factor receptor superfamily. Science (1997) 278:138–141.
  • •Initial characterisation of TACT.
  • XIA XZ, TREANOR J, SENALDI G et al.: TACT is a TRAF-interacting receptor for TALL-1, a tumour necrosis factor family member involved in B cell regulation. J. Exp. Med. (2000) 192:137–143.
  • YAN M, MARSTERS SA, GREWAL IS et al.: Identification of a receptor for BLyS demonstrates a crucial role in humoral immunity. Nat. Immunol. (2000) 1:37–41.
  • WU Y, BRESSETTE D, CARRELL JA et al.: Tumour necrosis factor (TNF) receptor superfamily member TACT is a high affinity receptor for TNF family members APRIL and BLyS. I Biol. Chem. (2000) 275:35478–35485.
  • VON BULOW GU, VAN DEURSEN JM, BRAM RJ: Regulation of the T-independent humoral response by TACT. Immunity (2001) 14:573–582.
  • YAN M, WANG H, CHAN B et al.: Activation and accumulation of B cells in TACT-deficient mice. Nat. Immunol. (2001) 2:638–643.
  • THOMPSON JS, BIXLER SA, QIAN F et al.: BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science (2001) 293:2108–2111.
  • ••First description of BAFF-R as a receptorspecific for BAFF and mediating its positive effect on B cell survival.
  • YAN M, BRADY JR, CHAN B et al.: Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency. Carr. Biol. (2001) 11:1547–1552.
  • ••Description of BAFF-R (BR3).
  • JOHNSTON J, HARDER B, MCMILLEN S et al: zTNF-R12, a novel receptor capable of binding BLyS. ACR Meeting, San Francisco, USA (2001) Abstract 672.
  • HARLESS SM, LENTZ VM, SAH AP et al.: Competition for BLyS-mediated signalling through Bcmd/BR3 regulates peripheral B lymphocyte numbers. Curt: Biol. (2001) 11:1986–1989.
  • LENTZ VM, CANCRO MP, NASHOLD FE, HAYES CE: Bcmd governs recruitment of new B cells into the stable peripheral B cell pool in the A/ WySnJ mouse. J. Immunol. (1996) 157:598–606.
  • MILLER DJ, HANSON KD, CARMAN JA, HAYES CE: A single autosomal gene defect severely limits IgG but not IgM responses in B lymphocyte-deficient A/WySnJ mice. Eur. I Immunol. (1992) 22:373–379.
  • AMANNA IJ, CLISE-DWYER K, NASHOLD FE, HOAG KA, HAYES CE: A/WySnJ transitional B cells overexpress the chromosome 15 proapoptotic Blk gene and succumb to premature apoptosis. Immunol. (2001) 167:6069–6072.
  • GROSS JA, DILLON SR, MUDRI S et al.: TACT-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS. Immunity (2001) 15:289–302.
  • MACKAY F, WOODCOCK SA, LAWTON P et al: Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. I Exp. Med. (1999) 190:1697–1710.
  • ••BAFF overexpression causes B cellhyperplasia and autoimrnunity in mice.
  • KHARE SD, SAROSI I, XIA XZ et al: Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc. Natl. Acad. Sci. USA (2000) 97:3370–3375.
  • ••BAFF overexpression causes B cellhyperplasia and autoimrnunity in mice.
  • WANG H, MARSTERS SA, BAKER T et al: TACT-ligand interactions are required for T cell activation and collagen-induced arthritis in mice. Nat. Immun.ol. (2001) 2:632–637.
  • ••Blockade of CIA by administration ofTACT-Fc.
  • HARDY RR, HAYAKAWA K: B cell development pathways. Ann. Rev Immunol (2001) 19:595–621.
  • CARIAPPA A, PILLAI S: Antigen-dependent B cell development. Carr: Opin. Immunol. (2002) 14:241–249.
  • •Excellent review of current knowledge on B cell development.
  • LODER F, MUTSCHLER B, RAY RJ et al: B cell development in the spleen takes place in discrete steps and is determined by the quality of B cell receptor-derived signals. J. Exp. Med. (1999) 190:75–89.
  • ALLMAN D, LINDSLEY RC, DEMUTH W et al.: Resolution of three non-proliferative immature splenic B cell subsets reveals multiple selection points during peripheral B cell maturation. J. Immunol. (2001) 167:6834–6840.
  • MARTIN F, KEARNEY JF: Marginal-zone B cells. Nat. Rev Immunol (2002) 2:323–335.
  • •Excellent up-to-date review on MZ B cell development and biology.
  • BATTEN M, GROOM J, CACHERO TG et al.: BAFF mediates survival of peripheral immature B lymphocytes. I Exp. Med. (2000) 192:1453–1465.
  • ROLINK AG, TSCHOPP J, SCHNEIDER P, MELCHERS F: BAFF is a survival and maturation factor for mouse B cells. Eur. Immunol. (2002) 32:2004–2010.
  • HSU BL, HARLESS SM, LINDSLEY RC, HILBERT DM, CANCRO MP: BLyS enables survival of transitional and mature B cells through distinct mediators. j. Immunol. (2002) 168:5993–5996.
  • HUARD B, SCHNEIDER P, MAURI D, TSCHOPP J, FRENCH LE: T cell costimulation by the TNF ligand BAFF. J. Immunol. (2001) 167:6225–6231.
  • ••BAFF is a costirnulator of T cell activation in vitro.
  • RUNKEL L, KUO F, CHICHEPORTICHE Y, TSCHOPP J, BROWNING JL: Null mutation of the TNF family member, APRIL results in embryonic death and cardiac defects. International Cytokine Society and Society for Leukocyte Biology Joint Conference. Maui, USA (2001).
  • STEIN JV, LOPEZ-FRAGA M, ELUSTONDO FA et al.: APRIL modulates B and T cell immunity. j Clin. Invest. (2002) 109:14587–14598.
  • GROOM J, KALLED SL, CUTLER AH et al.: Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. I. Clin. Invest. (2002) 109:59–68.
  • ••Demonstrates that BAFF overexpressioncauses salivary gland inflammation resembling Sjogren's syndrome in mice and suggests that MZ-like B cells may have a pathogenic role in this disease.
  • MINER KT, EASTMAN SR, XIA SZ et al.: Treatment with modified soluble TACI ameliorates autoimmune diseases by affecting humoral immune response. ACR Meeting, San Francisco, USA (2001) Abstract 2060.
  • ZHANG J, ROSCHKE V, BAKER KP et al.: A role for B lymphocyte stimulator in systemic lupus erythematosus. Immunol. (2001) 166:6–10.
  • ••Serum level of BAFF is augmented and partially associated with increased anti-dsDNA autoantibody titers in SLE patients.
  • CHEEMA GS, ROSCHKE V, HILBERT DM, STOHL W: Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritic Rheum. (2001) 44:1313–1319.
  • ••BAFF level is increased in the serum ofpatients with SLE or RA and in inflamed joints of the latter.
  • DAVIS JC, GROSS J, GESCUK B, HARDER B, WOFSY D: ZTNF-4 and soluble TACI receptor levels in serum and urine may reflect disease activity in patients with SLE. ACR Meeting, San Francisco, USA. (2001) Abstract 278.
  • KOBAYASHI S, MORIYAMA T, MUKAI M: Differential gene expression of BAFF, TACI and BCMA by peripheral blood mononuclear cells from patients with systemic lupus erythematosus. ACR Meeting, San Francisco, USA. (2001) Abstract 279.
  • MARIETTE X, ROUX S, DESMOULINS F et al.: A role for B lymphocyte stimulator (Blys) in Sjogren's syndrome. ACR Meeting, San Francisco, USA. (2001) Abstact 1205.
  • TAN SM, XU D, ROSCHKE V et al: Local production of B lymphocyte stimulator (BLyS) protein in human arthritic joints. ACR Meeting, San Francisco, USA. (2001) Abstract 1854.
  • ••BAFF production is locally increased injoints of RA patients.
  • ZHOU T, MARTIN F, LIU W et al.: Adenoviral delivery of TACI-Fc reverses autoimmunity in mice. ACR Meeting, San Francisco, USA. (2001) Abs 2061.
  • HOLMDAHL R, BOCKERMANN R, BACKLUND J, YAMADA H: The molecular pathogenesis of collagen-induced arthritis in mice - a model for rheumatoid arthritis. Ageing Res. Rev. (2002) 1:135–147.
  • ZHANG HG, YANG P, XIE J et al: Depletion of collagen II-reactive T cells and blocking of B cell activation prevents collagen II-induced arthritis in DBA/lj mice. J. Immunol. (2002) 168:4164–4172.
  • ROTH W, WAGENKNECHT B, KLUMPP A et al.: APRIL, a new member of the tumour necrosis factor family, modulates death ligand-induced apoptosis. Cell Death Differ. (2001) 8:403–410.
  • GHETIE V, WARD ES: Multiple roles for the major histocompatibility complex class I-related receptor FcRn. Ann. Rev Immunol. (2000) 18:739–766.
  • CHAN FK, CHUN HJ, ZHENG Let al.: A domain in TNF receptors that mediates ligand-independent receptor assembly and signalling. Science (2000) 288:2353–2354.
  • SEKUT L, STURM B, POORTMAN C et al.: characterisation of a human monoclonal antibody that antagonizes B lymphocyte stimulator bioactivities. ACR Meeting, San Francisco, USA. (2001) Abstract 1377.
  • ••Description of a human anti-BAFF mAbthat neutralises BAFF bioactivities in vitro and in vivo.
  • BRIONES J, TIMMERMAN JM, HILBERT DM, LEVY R: BLyS and BLyS receptor expression in nonHodgkin's lymphoma. Exp. Hematol. (2002) 30:135–141.
  • RICCOBENE T, SUNG C, ALDERSON RF et al.: Radiolabelled BLyS protein (LR131) inhibits neoplastic B cell growth in vivo. American Society of Clinical Oncology 38th Annual Meeting, Orlando, USA. (2002) Abstract 39.
  • ••Evidence that radioiodinated BAFF inhibitsthe growth of malignant B cells in vivo.
  • PARRY TJ, RICCOBENE TA, STRAWN SJ et al.: Pharmacokinetics and immunological effects of exogenously administered recombinant human B lymphocyte stimulator (BLyS) in mice. Pharmacol. Exp. Ther. (2001) 296:396–404.
  • ••Administration of recombinant BAFFenhances B cell immunity in mice.
  • SNELLER MC: Common variable immunodeficiency. Am. .1. Med. Sci. (2001) 321:42–48.
  • ARKWRIGHT PD, ABINUN M, CANT AJ: Autoimmunity in human primary immunodeficiency diseases. Blood (2002) 99:2964–29702.
  • CUNNINGHAM-RUNDLES C: Physiology of IgA and IgA deficiency. Clin. Immunol. (2001) 21:303–309.
  • MOSCA M, RUIZ-IRASTORZA G, KHAMASHTA MA, HUGHES GR: Treatment of systemic lupus erythematosus. Int. Immunopharmacol. (2001) 1:1065–1075.
  • MARRACK P, KAPPLER J, KOTZIN BL: Autoimmune disease: why and where it occurs. Nat. Med. (2001) 7:899–905.
  • DAVIDSON A, DIAMOND B: Autoimmune diseases. N Engl. I Med. (2001) 345:340–350.
  • JIANG Y, OHTSUJI M, ABE M et al.: Polymorphism and chromosomal mapping of the mouse gene for B cell activating factor belonging to the tumour necrosis factor family (Baff) and association with the autoimmune phenotype. Immunogenetics (2001) 53:810–813.
  • LITINSKY MB, NARDELLI B, HILBRERT DM et aL:DCs induce SCD40-independent immunoglobulin class switching through BlyS and APRIL. Nat. Immunol. (2002) 3: (In Press).
  • GRILLO-LOPEZ AJ, HEDRICK E, RASHFORD M, BENYUNES M:Rituximab: ongoing and future clinical development. Semin. Oncol (2002) 29:105–112.
  • ANOLIK JH, CAMPBELL D, RITCHLIN C et al.: B lymphocyte depletion as a novel treatment for systemic lupus erythematosus (SLE): Phase I/II trial of ritwdmab (Rituxanl in SLE. ACR Meeting, San Francisco, USA. (2001) Abstract 2009.
  • ZAJA F, IACONA I, MASOLINI P et al.: Bcell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. Hatanatologica (2002) 87:189–195.
  • MARTIN F, KEARNEY JF: B1 cells: similarities and differences with other B cell subsets. Curt: Opin. Inonunoi (2001) 13:195–201.

Websites

  • www.zymogenetics.com ZymoGenetics: Press release. ZymoGenetics and Serono to collaborate on a novel therapeutic approach for autoimmune disease. 4 Sept 2001.
  • www.apoxis.com Apoxis Biosciences.
  • www.hgsi.com Human Genome Sciences: Press release. Human Genome Sciences initiates trial of a new drug for systemic lupus erythematosus and other autoimmune disease. 1 Nov 2001.
  • www.hgsi.com Human Genome Sciences: Press release. Human Genome Sciences files investigational new drug application for LymphoRad131. 23 Jan 2002.
  • www.hgsi.com Human Genome Sciences: Press release. Human Genome Sciences announces clearance of investigational new drug application for LymphoRad131, a new anticancer drug for the treatment of B cell tumours. 14 May 2002.
  • www.hgsi.com Human Genome Sciences: Press release. Human Genome Sciences to initiate human clinical trials of BLyS. Trials to begin only one year after discovery announced, 23 June 2000.
  • www.hgsi.com Human Genome Sciences: Press release. Human Genome Sciences receives orphan drug designation for BLyS therapeutic protein for treatment of common variable immunodeficiency. 27 Feb 2001.
  • www.hgsi.com Human Genome Sciences: Press release. Human Genome Sciences announces trial for treatment of immunoglobulin-A deficiency. 19 Sept 2001.
  • www.roche.com Roche: Press release. Targeting rheumatoid arthritis - New hope with smart drug ritwdmab. Interim study results indicate ritwdmab may help improve lives of people with rheumatoid arthritis.19 June 19 2002:

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.